Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

Overview
Date Founded

1998

Headquarters

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, 48108, USA

Type of Company

Public

Employees (Worldwide)

76

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). It offers Bempedoic acid and Ezetime combination pill as therapies that have been shown to lower elevated LDL-C levels in patients with hypercholesterolemia, including patients inadequately treated with current lipid-modifying therapies. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

Contact Data
Trying to get in touch with decision makers at Esperion Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

President & Chief Executive Officer

Chief Financial Officer & Principal Financial Officer

Chief Development Officer

Chief Medical Officer

Executive Vice President, Research & Development

Senior Vice President

Senior Vice President, Clinical Development

Senior Vice President of Technical Operations

Project Manager

Board of Directors

Chief Executive Officer & Director at Real Endpoints LLC

President, Chief Executive Officer & Director at Aravive, Inc.

Partner at Domain Associates LLC

President & Vice President at Alta Partners III, Inc.

Chief Operating Officer & Director at Stat Medical Services, Inc.

President & Chief Executive Officer at Esperion Therapeutics, Inc.

Director at Cempra Pharmaceuticals, Inc.

Former Chief Commercial Officer at Aravive, Inc.

Former Executive Director-Heart Failure at Bristol-Myers Squibb Company

Paths to Esperion Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Esperion Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm's in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech's investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Details Hidden

Meditor is an active, long-term, generalist, fundamentals-based manager which employs a bottom-up approach to invest in European equities. They have a specialization in healthcare and consumer goods.The firm invests across market caps and believes that different companies need to be measured by different metrics. Their investment managers conduct an extensive program of company visits complemented by external research from a network of consultants.Meditor's investment style is pro-active and event-driven, involved in turnaround investments, with a preference for the technology sector. The firm has previously invested in troubled companies, implemented management shake-ups, subsequently selling business branches to unlock value.

Details Hidden

PCM seeks to provide clients with consistently superior risk-adjusted rates of return through implementing event-driven strategies. Their investment strategies generally focus on an event or a catalyst that will move an equity price, an equity spread, a credit spread, or an implied volatility spread. Their investment strategies may include: merger arbitrage, catalyst-driven credit investing, special situation investing and distressed investing. Catalyst events may include mergers, acquisitions, spin-offs, carve-outs, tender offers, split-off exchange offers, share class spreads, re-organizations and corporate distress. PCM seeks to trade in all forms of the capital structure of companies involved in catalysts and events and to create the best risk/reward trade possible within the corporate capital structure. They attempt to limit risk through diversification and hedging. The firm may choose to take control positions in an attempt to create their own catalyst or event. In managing the fund's portfolio, PCM relies on fundamental analysis supplemented by quantitative analytics and portfolio management techniques. They take both long and short positions for their clients in a broad range of public and private debt securities, equity securities, options, derivatives and credit derivatives (including credit default swaps), trade claims, bank debt participations and other instruments. PCM invests within and outside of the US, as well as in issuers in various stages of financial distress.

Recent Transactions
Details Hidden

Esperion Therapeutics, Inc. issued USD Common Stock

Details Hidden

Esperion Therapeutics, Inc. issued Common Stock

Details Hidden

Esperion Therapeutics, Inc. issued Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onEsperion Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onEsperion Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onEsperion Therapeutics, Inc. issued USD Common Stock

Managing Director

Advised onEsperion Therapeutics, Inc. issued Common Stock

Professional

Advised onEsperion Therapeutics, Inc. issued Common Stock

Legal Advisor

Advised onEsperion Therapeutics, Inc. issued Common Stock

Advisors & Consultants
Legal Advisor

Partner at Davis Polk & Wardwell LLP

Publicist

Media Relations Contact at The W2O Group

Clients

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2018
Market Capitalization
$1.35B
Total Enterprise Value
$1.09B
Earnings Per Share
$-7.54
Revenue
$0
Net Profit
$-202M
EBITDA
$-204M
Total Debt
$0
Total Equity
$79.1M
TEVNet Income
-5.42x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
0%
Five Year Compounded Annual Growth Rate Of Revenue
0%
Non-Profit Donations & Grants
Investors
Details Hidden

Managing Partner at Oak Investment Partners

Details Hidden

Longitude Capital invests in growth capital investments in biotechnology and medical technology. They consider companies across all therapeutic indications and stages of development.

Details Hidden

Aisling Capital LLC invests in private and small cap publicly traded equities located in the US. The firm targets companies operating in the fields of developing & commercializing important and innovative healthcare products, services & technologies. It provides equity, debt and other structured securities financing for royalty deals, large cap leveraged buyout, seed and venture financing of development stage companies.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Alnylam Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, MA

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Esperion Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Esperion Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Esperion Therapeutics, Inc..